Clinical trial
Satralizumab,an Anti-IL-6 Receptor Antibody, in the Treatment of Pulmonary Arterial Hypertension; Safety and Efficacy Evaluation in Japan -Multicenter, Investigator-sponsored Trial-
NCT05679570 is registered in ClinicalTrials.gov with International University of Health and Welfare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Satralizumab,an Anti-IL-6 Receptor Antibody, in the Treatment of Pulmonary Arterial Hypertension; Safety and Efficacy Evaluation in Japan -Multicenter, Investigator-sponsored Trial-
- Lead sponsor
- International University of Health and Welfare
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 12, 2022
- Completion date
- April 14, 2026
- Enrollment
- 20 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.